GlobeNewswire

2024-10-16 21:00

RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category, recognizing its intuitive pairing of NPWT housed in a patient-friendly design.

The Red Dot Awards celebrate new innovations and groundbreaking designs, with recipients ranging from concepts and prototypes to full Ready For Market products.

Launched in 2024, the RENASYS EDGE NPWT System is a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities.1


It is estimated that the annual financial burden of chronic wounds in the US is $33 billion,2 and affecting some 8.2 million people.*3 The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated.4 The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort.

Smith+Nephew’s PICO 14 NPWT System also won a Red Dot Award for Design Concept in 2021 for its lightweight, discreet and portable design which provides patients with high mobility.5-7

-ends-

Enquiries

Media

Dave Snyder+1 978-749-1440
Smith+Nephewdave.snyder@smith-nephew.com
  

* based on Medicare beneficiaries

References

  1. Smith+Nephew 2022. Internal Report. EO.AWM.PCS270.003.v1.
  2. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014 Mar;37(3):651-8. Numbers are rounded where appropriate.
  3. Sen CK. Human wounds and its burden: An updated compendium of estimates. Advances in Wound Care, 2019; 8(2):39-48
  4. Phillips T, StantonB, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31(1):49–53
  5. Gilchrist B, et al. Paper presented at: SAWC; 2020; Virtual.
  6. Smith+Nephew 2020. Internal Report. 2001002.
  7. Smith+Nephew 2018. Internal Report. DS.18.066.R.

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use. 

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on XLinkedInInstagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


Primary Logo

source: Smith & Nephew UK Ltd

【你點睇】美國總統拜登卸任前宣布特赦兒子亨特拜登,你認為美國民主及法治制度是否已經受損?► 立即投票

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞睇住賞Maxcare美天膝健寶(價值HK$2,699)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

Watche Trends 2024

北上食買玩

Art Month 2024

理財秘笈

秋天養生食療

消委會報告

山今養生智慧

輕鬆護老